Live Herpes Zoster Vaccine Fails to Provide Long-Term Protection in RA Patients on Tofacitinib

(Reuters Health)—The live herpes zoster vaccine does not provide reliable long-term protection in rheumatoid arthritis (RA) patients taking tofacitinib, a recent study suggests. Current ACR guidelines conditionally recommend that patients with RA who are 50 years and older be vaccinated against herpes zoster prior to starting therapy with the Janus kinase (JAK) inhibitor tofacitinib or... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions Rheumatoid Arthritis herpes zoster Rheumatoid Arthritis (RA) shingles Shingrix Tofacitinib vaccine Source Type: research